Exova Group PLC Acquisition (2115C)
11 April 2017 - 4:30PM
UK Regulatory
TIDMEXO
RNS Number : 2115C
Exova Group PLC
11 April 2017
STOCK EXCHANGE RELEASE
11 April 2017
Exova Group plc
Exova acquires SL Pharma Labs Incorporated
Exova Group plc ("Exova") EXO.L, the global testing, calibration
and advisory services provider, has acquired SL Pharma Labs
Incorporated (SL Pharma), a Delaware, US, based business that
provides laboratory and clinical manufacture testing services to
pharmaceutical, biotechnology and medical device companies.
Founded in 1997, SL Pharma has built a strong reputation in the
provision of high value and high quality pharmaceutical product
development and testing services focused primarily on the
development and clinical manufacture of parenteral, ophthalmic,
intranasal and topical drug products. The business has a team of 14
specialists and achieved revenues of around $2.5m in 2016.
Ian El-Mokadem, Chief Executive Officer at Exova, said: "This
acquisition complements our existing operations by enhancing
Exova's technical expertise in pharmaceutical services and offers a
great foundation for further growth in North America. SL Pharma's
addition to our portfolio clearly demonstrates our commitment to
providing more technically demanding services and developing our
capabilities in new markets."
ENDS
Enquiries:
Andy Jones
Powerscourt
T: +44 (0) 20 7549 0747
E: andy.jones@exova.com
Andrew Pickup
Corporate Affairs Director, Exova Group plc
T: +44 (0) 7920 243 393
E: andrew.pickup@exova.com
Exova
Exova is one of the world's leading laboratory-based testing
groups, trusted by organisations to test and advise on the safety,
quality and performance of their products and operations.
Headquartered in Edinburgh, UK, Exova operates 135 laboratories and
offices in 33 countries and employs around 4,200 people throughout
Europe, the Americas, the Middle East, Asia/Asia Pacific and
Africa.
Exova's capabilities help to extend asset life, bring
predictability to applications, and shorten the time to market for
customers' products, processes and materials. With over 90 years'
experience, Exova specialises in testing across a number of key
sectors ranging from Aerospace to Fire & Building Products; Oil
& Gas and Industrials; Infrastructure & Environment;
Transportation; and Health Sciences.
Exova Group plc is registered in England (registration number
08907086). Its legal entity identifier ('LEI') number is
213800BFE317FGSYMZ19.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQBBGDSSGBBGRB
(END) Dow Jones Newswires
April 11, 2017 10:30 ET (14:30 GMT)
Exova (LSE:EXO)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Exova (LSE:EXO)
Historical Stock Chart
Von Jul 2023 bis Jul 2024